Compare Acadia Healthcare Company Inc (ACHC) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Acadia Healthcare Company Inc vs Merck & Co., Inc. — how do they compare? Acadia Healthcare Company Inc trades at $30.67 (market cap $2.94B), while Merck & Co., Inc. trades at $126.01 (market cap $318.26B). The key difference: Merck & Co., Inc. is far larger — about 108.3× Acadia Healthcare Company Inc's market cap, and Merck & Co., Inc. pays a 2.64% dividend while Acadia Healthcare Company Inc pays none. Which is the better fit depends on your goals.
| ACHC | MRK | |
|---|---|---|
Market Cap | $2.94B | $318.26B |
Sector | Health | Health |
52-Week High | $31.92 | $129.52 |
52-Week Low | $11.68 | $77.60 |
Enterprise Value | $5.45B | $361.68B |
Dividend Yield | — | 2.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACHC trades at $31.09, down 2.57% today but maintains a bullish technical outlook with strong moving average support. The company shows operational strength with three consecutive earnings beats, though profitability remains challenged with a -32.84% net margin. Analyst consensus is strongly bullish with 68% buy ratings, while recent news highlights the company's strategic shift toward profitability and rising behavioral health demand.
The stock presents a mixed opportunity with strong technical momentum and analyst support offset by persistent profitability challenges. Key catalysts include continued earnings outperformance and successful execution of the turnaround strategy, while risks center on margin pressures and high short interest that could limit upside potential.
Merck (MRK) trades at $126.00, down 0.62% today, with a bullish technical outlook supported by moving averages and strong institutional buying. The company reported solid earnings beats in recent quarters, with Q1 2026 loss narrower than expected. Revenue reached $65.01B in 2025, with net income margin improving to 28.07%. Recent acquisition of Terns Pharmaceuticals for approximately $6.7 billion aims to bolster its oncology pipeline, reflecting strategic growth initiatives.
Outlook remains positive with a consensus price target of $139.33, implying 11% upside, supported by 67.6% analyst buy ratings. Risks include rising debt-to-asset ratio to 36.06% in 2025 and projected net cash flow decline to -$3.3B in 2026. Competitive pressures in pharma and macroeconomic uncertainties could challenge growth, but strong profitability and dividend yield offer defensive appeal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Acadia Healthcare Company Inc
Acadia Healthcare is a leading provider of behavioral healthcare services across the US and Puerto Rico. It operates a network of psychiatric hospitals, residential treatment centers, and clinics for mental health and addiction recovery.
Read more on ACHC →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
